Moderna, Inc. MRNA
Follow Moderna free
Follow free
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Updated: 21 Sep 2026
Base analysis: 20 Aug 2026
The news check keeps the assessment current.
General analysis — not personal advice.
HOLD
Clear
Existing positions can be maintained while new investors await further data.
Strong cash position and positive phase 3 data are balanced against ongoing losses, patent risks and execution challenges, supporting a neutral signal.
Market sentiment
Positive ↑
Trend: Improving
The market reacts positively to the phase 3 breakthrough for the cancer vaccine but shows increased caution after the patent decision and analyst downgrade.
Risk assessment
Medium
Dilution:
Low
Strong cash provides more than 24 months runway
Jurisdiction:
Low
Primary operations in USA and Europe
Execution:
High
Pipeline delivery and commercial scaling remain to be proven
Cash flow:
24 mo
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
About the company
Moderna develops and commercializes mRNA-based vaccines and therapies. The company has products including Spikevax for COVID-19, mRESVIA for RSV and a recently approved influenza vaccine. The pipeline includes personalized cancer vaccines in partnership with Merck as well as programs for norovirus and rare diseases.
Sector:
MRNA-based vaccines and therapies
Type:
Biotech
Next report (Q3)
15 Nov 2026
Catalysts
Q4 2026
Norovirus phase 3 data
Medium
Bull case
Positive phase 3 results for intismeran in melanoma drive regulatory interest and validate the mRNA platform.
Bear case
Continued large net losses, patent challenges and uncertain commercial scaling limit profitability.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| intismeran phase 3 results | Failed regulatory discussions → delayed or no launch of cancer vaccine reduces diversification potential. | Successful regulatory path → broadened oncology portfolio and higher long-term revenue potential. |
| mFLUSIVA launch | Weak initial sales → continued reliance on COVID revenues and higher burn rate. | Strong adoption → faster revenue growth and improved profitability outlook. |
Why this signal
Strong cash position and positive phase 3 data are balanced against ongoing losses, patent risks and execution challenges, supporting a neutral signal.
Recent news
- Moderna and Merck reported that intismeran plus Keytruda met primary endpoints in the phase 3 melanoma study. The European Patent Office invalidated a key patent in the dispute with BioNTech/Pfizer. The company issued 2.6 billion USD senior convertible notes. The stock has consolidated around 140–154 USD after volatility.
Key figures
Revenue
Q2 2026
USD 145M
EBITDA
Q2 2026
USD -734M
Net income
Q2 2026
USD -0.8B
Cash
as_of
USD 6.9B
Gross margin
Q2 2026
36.0%
Shares outstanding
Q2 2026
397M
EPS
Q2 2026
USD -2.02
Exchange
NASDAQ
Type
Biotech
Sector
MRNA-based vaccines and therapies
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.